Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors ; volume:25 ; number:6 ; day:2 ; month:5 ; year:2024 ; pages:719-751 ; date:6.2024
Current treatment options in oncology ; 25, Heft 6 (2.5.2024), 719-751, 6.2024
- Urheber
-
Tecik, Melisa
Adan, Aysun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11864-024-01202-7
- URN
-
urn:nbn:de:101:1-2409231204015.377389722624
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tecik, Melisa
- Adan, Aysun
- SpringerLink (Online service)
Ähnliche Objekte (12)
FLT3-ITD regulated miRs in AML
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Identification of Protein Tyrosine Phosphatases regulating FLT3 activity and of PTPs regulated by FLT3 ITD
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Role of FLT3 ITD PTPRC signaling in bone remodeling
The role of STAT5 in FLT3-ITD-mediated leukemogenesis
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
FLT3-ITD regulated miRs in AML
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Identification of Protein Tyrosine Phosphatases regulating FLT3 activity and of PTPs regulated by FLT3 ITD
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Role of FLT3 ITD PTPRC signaling in bone remodeling
The role of STAT5 in FLT3-ITD-mediated leukemogenesis
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
FLT3-ITD regulated miRs in AML
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Identification of Protein Tyrosine Phosphatases regulating FLT3 activity and of PTPs regulated by FLT3 ITD
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Role of FLT3 ITD PTPRC signaling in bone remodeling
The role of STAT5 in FLT3-ITD-mediated leukemogenesis
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien